Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study
Robert Gilmore(The University of Queensland), Jakob Begun(Translational Research Institute), Rupert W. Leong(The University of Sydney), Imogen Hartley(St Vincent's Hospital Melbourne), Britt Christensen(The Royal Melbourne Hospital), Abhey Singh(Fiona Stanley Hospital), Abhinav Vasudevan(Eastern Health), Steven Kim(California State University, Monterey Bay), Bridgette Andrew(Eastern Health), Nik S. Ding(The University of Melbourne), Yoon‐Kyo An(Mater Hospital), Richard Fernandes(The University of Queensland), Gregory Moore(Monash Medical Centre), Jonathan Segal(The Royal Melbourne Hospital), Jack West(The Royal Melbourne Hospital), Tessa Greeve(Monash Health), Aditya Mithanthaya(Royal Perth Hospital), Sangwoo Han(Queen Elizabeth Hospital), Crispin Corte(Royal Prince Alfred Hospital), Kannan Venugopaul(Royal Perth Hospital), Robert V. Bryant(Queen Elizabeth Hospital), Arteen Arzivian(Macquarie University), Daniel Lightowler(The University of Western Australia)
Cited by 13
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes
|Clinical Gastroenterology and Hepatology|2017|234
Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci
|Proceedings of the National Academy of Sciences|2007|219